Neurobehavioral Disorders
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Neurobehavioral Disorders
Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.
Neurobehavioral Disorders
Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.
Neurobehavioral Disorders
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Neurobehavioral Disorders
This was a study protocol for a phase II pilot feasibility study that will assess the feasibility of ketamine for depression in patients with advanced life-limiting illnesses.
Neurobehavioral Disorders
Ensemble is an AI-powered digital mental health coach app designed to address the symptoms of MDD or GAD.
Neurobehavioral Disorders
Patients with depression can live with symptoms for a long period of time before finding an option that works. One possibility for patients who are unable to find relief through pharmacology is transcranial magnetic stimulation. An expert offers his view on this form of treatment.
Neurobehavioral Disorders
Major depressive episodes reduce visual contrast suppression among patients with depressive disorders, a study shows.
Neurobehavioral Disorders
Psilocybin has been shown to have antidepressant properties. With direct comparisons between psilocybin and established treatments for depression lacking, the study researchers looked at psilocybin and escitalopram.
Neurobehavioral Disorders
AXS-05 consists of dextromethorphan, an NMDA receptor antagonist, and bupropion, a norepinephrine and dopamine reuptake inhibitor.
